Board Meeting On 11/08/2017
Board Meeting on 11/08/201703-08-2017
Shareholding for the Period Ended June 30, 2017
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here20-07-2017
Statement Of Investor Complaints For The Quarter Ended 30Th June, 2017
Statement of Investor Complaints for the quarter ended 30th June, 2017 under Regulation 13(3) of SEBI (LODR), 2015.11-07-2017
Board recommends Dividend
Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company has, at its meeting held on May 29, 2017, inter alia, has recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each value for the financial year ended March 31, 2017, subject to approval of the shareholders in the ensuing Annual General Meeting.29-05-2017
Outcome of Board Meeting
the Board of Directors of the Company has, at its meeting held on today i.e. Monday, 29th May, 2017 at Mumbai, recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each value for the financial year ended 31st March, 2017, subject to approval of the shareholders in the ensuing Annual General Meeting.29-05-2017
Board to consider FY results & Dividend on May 29, 2017
Marksans Pharma Ltd has informed BSE that the Meeting of the Board of Directors of the Company will be held on May 29, 2017, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended March 31, 2017. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2016-17....19-05-2017